NCT02843100 (DIETOMICS-CD) is a NA clinical trial of Modified Exclusive Enteral Nutrition in Crohn's Disease, sponsored by Prof. Arie Levine.

Who is sponsoring NCT02843100?

NCT02843100 is sponsored by Prof. Arie Levine.

What drugs are being tested in NCT02843100?

Interventions in NCT02843100: Modified Exclusive Enteral Nutrition, Crohn's Disease Exclusion Diet, Partial Enteral Nutrition, Standard Exclusive Enteral Nutrition.

What condition does NCT02843100 study?

NCT02843100 studies Crohn's Disease.

Is NCT02843100 still recruiting?

NCT02843100 is currently completed. Last updated 1 June 2022.

Last reviewed 2022-06-01 · How we verify

NCT02843100: DIETOMICS-CD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diet for Induction and Maintenance of Remission and Re-biosis in Crohn's Disease

Completed NA Last updated 1 June 2022

What this trial tests

NA trial testing Modified Exclusive Enteral Nutrition in Crohn's Disease in 63 participants. Completed in 29 May 2022.

Timeline

10 April 2018

Primary endpoint
29 May 2022

29 May 2022

Quick facts

Lead sponsor	Prof. Arie Levine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	63
Start date	10 April 2018
Primary completion	29 May 2022
Estimated completion	29 May 2022
Sites	7 locations across Ireland, Canada, Israel, Spain

Drugs / interventions tested

Modified Exclusive Enteral Nutrition
Crohn's Disease Exclusion Diet
Partial Enteral Nutrition
Standard Exclusive Enteral Nutrition

Conditions studied

Crohn's Disease — all drugs for Crohn's Disease →

Sponsor

Prof. Arie Levine

Who can join

Adults 8 to 18, any sex, with Crohn's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The modified-Exclusive Enteral Nutrition (mEEN) is an open label randomized controlled trial in mild to severe Crohn's Disease patients. The purpose of this study is to determine whether induction of remission and maintenance of remission can be achieved with a new dietary strategy that involves only 2 weeks of Exclusive Enteral Nutrition (EEN) with Modulen and 12 weeks of an exclusion diet involving selected table foods. This novel approach will be compared to the gold standard dietary regime involving 8 weeks of EEN.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Enteral nutritional therapy for induction of remission in Crohn's disease.
Narula N, Dhillon A, Zhang D, Sherlock ME, et al · · 2018 · cited 144× · PMID 29607496 · DOI 10.1002/14651858.cd000542.pub3
Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases.
Oka A, Sartor RB. · · 2020 · cited 126× · PMID 32006212 · DOI 10.1007/s10620-020-06090-z
Enteral nutrition for maintenance of remission in Crohn's disease.
Akobeng AK, Zhang D, Gordon M, MacDonald JK. · · 2018 · cited 18× · PMID 30098021 · DOI 10.1002/14651858.cd005984.pub3
Modified Crohn's Disease Exclusion Diet Maintains Remission in Pediatric Crohn's Disease: Randomized Controlled Trial.
Sigall Boneh R, Navas-López VM, Hussey S, Pujol-Muncunill G, et al · · 2025 · cited 6× · PMID 39732356 · DOI 10.1016/j.cgh.2024.12.006
Reply to Cantarelli et al. Chronic Recurrent Multifocal Osteomyelitis Associated with Crohn Disease: A Potential Role of Exclusion Diet? Comment on "Starz et al. The Modification of the Gut Microbiota via Selected Specific Diets in Patients with Crohn's Disease. <i>Nutrients</i>
Starz E, Wzorek K, Folwarski M, Kaźmierczak-Siedlecka K, et al · · 2021 · cited 3× · PMID 34836262 · DOI 10.3390/nu13114007
Are Nutrition Interventions to Augment Treatment Plans the Most Personalized Approach to Inflammatory Bowel Disease Therapy?
Barnes EL. · · 2020 · cited 1× · PMID 36776502 · DOI 10.1093/crocol/otaa043
Abstract
· 2025

Verify or expand the search:

Other recruiting trials for Crohn's Disease

Currently open trials in the same condition.

NCT07273188 — 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease · EARLY_PHASE1 · recruiting
NCT07184944 — A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Acti · Phase 3 · recruiting
NCT07242248 — A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disea · recruiting
NCT06405087 — A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD · Phase 3 · recruiting
NCT07184931 — An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ · Phase 3 · recruiting

Other Prof. Arie Levine trials

Trials by the same sponsor.

NCT03980405 — Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis · NA · terminated
NCT02345733 — Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02843100 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prof. Arie Levine
Last refreshed: 1 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02843100.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing